Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies

• Published in: Journal of pharmaceutical and biomedical analysis 2020-02, Vol.180, p.113019-113019, Article 113019
• Main Authors: King, Tamara I., Sharma, Abhisheak, Kamble, Shyam H., León, Francisco, Berthold, Erin C., Popa, Raluca, Cerlati, Orélia, Prentice, Boone M., McMahon, Lance R., McCurdy, Christopher R., Avery, Bonnie A.
• Format: Article
• Language: English
• Subjects: Alkaloid; Alkaloids - pharmacokinetics; Animals; Biological Availability; Biosensing Techniques; Blood Specimen Collection; Chromatography, High Pressure Liquid; Corynantheidine; Kratom; Limit of Detection; Male; Mitragyna - chemistry; Mitragyna - metabolism; Mitragyna speciosa; Narcotic Antagonists - pharmacokinetics; Pharmacokinetics; Plant Extracts - pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; UPLC-MS/MS
• ISSN: 0731-7085; 1873-264X
• DOI: 10.1016/j.jpba.2019.113019

•A UPLC-MS/MS method was developed and validated for the quantification of corynantheidine.•Mass spectrometry imaging showed the distribution of corynantheidine in the whole rat brain.•Preclinical PK studies were performed for corynantheidine in Sprague Dawley rats. Corynantheidine, a minor alkaloid found in Mitragyna speciosa (Korth.) Havil, has been shown to bind to opioid receptors and act as a functional opioid antagonist, but its unique contribution to the overall properties of kratom remains relatively unexplored. The first validated bioanalytical method for the quantification of corynantheidine in rat plasma is described. The method was linear in the dynamic range from 1–500 ng/mL, requires a small plasma sample volume (25 μL), and a simple protein precipitation method for extraction of the analyte. The separation was achieved with Waters BEH C18 2.1 × 50 mm column and the 3-minute gradient of 10 mM ammonium acetate buffer (pH = 3.5) and acetonitrile as mobile phase. The method was validated in terms of accuracy, precision, selectivity, sensitivity, recovery, stability, and dilution integrity. It was applied to the analysis of the male Sprague Dawley rat plasma samples obtained during pharmacokinetic studies of corynantheidine administered both intravenously (I.V.) and orally (P.O.) (2.5 mg/kg and 20 mg/kg, respectively). The non-compartmental analysis performed in Certara Phoenix® yielded the following parameters: clearance 884.1 ± 32.3 mL/h, apparent volume of distribution 8.0 ± 1.2 L, exposure up to the last measured time point 640.3 ± 24.0 h*ng/mL, and a mean residence time of 3.0 ± 0.2 h with I.V. dose. The maximum observed concentration after a P.O. dose of 213.4 ± 40.4 ng/mL was detected at 4.1 ± 1.3 h with a mean residence time of 8.8 ± 1.8 h. Absolute oral bioavailability was 49.9 ± 16.4 %. Corynantheidine demonstrated adequate oral bioavailability, prolonged absorption and exposure, and an extensive extravascular distribution. In addition, imaging mass spectrometry analysis of the brain tissue was performed to evaluate the distribution of the compound in the brain. Corynantheidine was detected in the corpus callosum and some regions of the hippocampus.